US Patent Issued to Hangzhou Innogate Pharma on Sept. 16 for "Heterocyclic compound as CDK-HDAC double-channel inhibitor" (Chinese Inventors)

ALEXANDRIA, Va., Sept. 17 -- United States Patent no. 12,415,797, issued on Sept. 16, was assigned to Hangzhou Innogate Pharma Co. Ltd. (Zheijian, China).

"Heterocyclic compound as CDK-HDAC double-channel inhibitor" was invented by Hancheng Zhang (Zhejiang, China), Xiangyang Ye (Zhejiang, China) and Xin Cheng (Zhejiang, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention provides compounds of formula (I) as shown below, including their possible enantiomers and diastereomers, as well as pharmaceutically acceptable salts, hydrates or solvates thereof. The invention also provides pharmaceutical compositions of these compounds, methods for their preparation, and their use in the treatment of disea...